NAMS
NewAmsterdam Pharma Company N.V.
$27.05
+$0.36(+1.35%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$2.76B
Volume
711.97K
52W Range
$14.06 - $27.35
Target Price
$41.50
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $102.7M | $14.1M | $45.6M | ||
| Total Revenue | $102.7M | $14.1M | $45.6M | ||
| GROSS PROFIT | |||||
| Gross Profit | $102.7M | $14.1M | $45.6M | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $106.3M | $197.1M | $221.9M | ||
| Research & Development | $86.7M | $159.4M | $151.4M | ||
| Research Expense | $86.7M | $159.4M | $151.4M | ||
| Selling, General & Administrative | $19.5M | $37.6M | $70.4M | ||
| Selling & Marketing Expenses | $5.5M | -- | -- | ||
| General & Administrative Expenses | $19.5M | $37.6M | $70.4M | ||
| Salaries & Wages | $4.2M | $24.6M | $33.6M | ||
| Depreciation & Amortization | $72.0K | $115.0K | $299.0K | ||
| Depreciation & Amortization | $72.0K | -- | -- | ||
| OPERATING INCOME | |||||
| Operating income | $-3.6M | $-183.0M | $-176.3M | ||
| EBITDA | $-22.3M | $-176.9M | $-241.7M | ||
| NON-OPERATING ITEMS | |||||
| Interest Expense (Non-Operating) | $287.0K | -- | -- | ||
| Intinc | $11.0K | $11.3M | $16.9M | ||
| Net Non-Operating Interest Income/Expense | $-287.0K | $11.3M | $16.9M | ||
| Other Income/Expense | $-18.8M | $-5.2M | -- | ||
| SPECIAL ITEMS | |||||
| Special Income Charges | $-271.0K | -- | -- | ||
| PRE-TAX INCOME | |||||
| EBIT | $-22.3M | $-176.9M | $-241.6M | ||
| Pre-Tax Income | $-22.6M | $-176.9M | $-241.6M | ||
| INCOME TAX | |||||
| Tax Provision | -- | $27.0K | $-1.0K | ||
| NET INCOME | |||||
| Net Income | $-22.6M | $-176.9M | $-241.6M | ||
| Net Income (Continuing Operations) | $-22.6M | $-176.9M | $-241.6M | ||
| Net Income (Discontinued Operations) | $-22.6M | $-176.9M | $-241.6M | ||
| Net Income (Common Stockholders) | $-22.6M | $-176.9M | $-241.6M | ||
| Normalized Income | -- | -- | $-241.6M | ||
| TOTALS | |||||
| Total Expenses | $106.3M | $197.1M | $221.9M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $23.6M | $82.3M | $94.4M | ||
| Average Shares Outstanding (Diluted) | $23.6M | $82.3M | $94.4M | ||
| Shares Outstanding | $81.6M | $89.3M | $109.8M | ||
| Basic EPS | $-0.96 | $-2.15 | $-2.56 | ||
| Basic EPS (Continuing Operations) | $-0.96 | $-2.15 | $-2.56 | ||
| Diluted EPS | $-0.96 | $-2.15 | $-2.56 | ||
| Diluted EPS (Continuing Operations) | $-0.96 | $-2.15 | $-2.56 | ||
| OTHER METRICS | |||||
| Commission Expenses | $2.5M | -- | -- | ||
| Insurance And Claims | $289.0K | -- | -- | ||
| Other Gand A | $19.5M | $37.6M | $70.4M | ||
| Write Down | $271.0K | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $27.05 | +1.3% | 711.97K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW